에 대한 최신 뉴스 Teladoc Health (NYSE:TDOC) 주식

TELADOC HEALTH INC

Teladoc Health

Teladoc Health Inc is engaged in virtual care, forging a new healthcare experience with Better convenience, outcomes, and value. Its mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems.

ASTSpaceMobile.Screenshotvideo

Equities

Mid Cap

News

Movers

Tech

Trading Ideas

ASTS

IREN

MGNI

OKLO

TDOC

VNET

이 10개 중형주는 지난주 최고의 성과를 거두었습니다. 그것들이 당신의 포트폴리오에 있나요? 1. 킹소프트 클라우드(NASDAQ:KC)의 주식은 34.77% 상승했다.

AST 스페이스모바일, 텔레닥 헬스 및 아이렌 등 지난주 최대 상승한 중형주 (2월 3일-2월 7일)

Doctor Looking At Human Teeth X-ray

Earnings

Guidance

Health Care

After-Hours Center

텔레닥 헬스(NYSE:TDOC)의 주가는 회사가 분석가 기대치를 뛰어넘는 3분기 재무 결과를 보고한 후 수요일 시간외 거래에서 11% 이상 급등했다.

텔레닥 헬스의 주식은 예상을 넘는 3분기 실적에 시간외 거래에서 11% 이상 급등

cathie_wood_bz_ark

Markets

$BTC

$ETH

ARKF

ARKK

ARKW

COIN

PINS

수요일에 캐시 우드가 주도하는 아크 인베스트(Ark Invest)는 어드밴스드 마이크로 디바이시스(NASDAQ:AMD), 핀터레스트(NYSE:PINS), 코인베이스 글로벌(NASDAQ:

아크 인베스트가 AMD 주식을 $47.5백만 그리고 핀터레스트 주식을 $12.7백만 매수

Teladoc Health Inc

Wells Fargo analyst Stan Berenshteyn maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Equal-Weight and lowers the price target from $10 to $8.

Price Target

Analyst Ratings

Wells Fargo Maintains Equal-Weight on Teladoc Health, Lowers Price Target to $8

Canaccord Genuity analyst Richard Close maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Buy and lowers the price target from $14 to $12.

Canaccord Genuity Maintains Buy on Teladoc Health, Lowers Price Target to $12

Goldman Sachs analyst David Roman maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Buy and lowers the price target from $13 to $10.

Goldman Sachs Maintains Buy on Teladoc Health, Lowers Price Target to $10

Stifel analyst David Grossman maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Hold and lowers the price target from $9 to $8.

Stifel Maintains Hold on Teladoc Health, Lowers Price Target to $8

Evercore ISI Group analyst Elizabeth Anderson maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a In-Line and lowers the price target from $8 to $7.

Evercore ISI Group Maintains In-Line on Teladoc Health, Lowers Price Target to $7

Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $11.34, a high estimate of $16.00, and a low estimate of $8.00. A decline of 5.03% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1746100892_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Teladoc Health among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Grosslight</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$8.75</td>
<td>$11.00</td>
</tr>
<tr>
<td>Glen Santangelo</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$8.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$8.00</td>
<td>$9.50</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$13.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$16.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$13.50</td>
<td>$11.50</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$11.50</td>
<td>$10.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Teladoc Health. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Teladoc Health compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Teladoc Health's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Teladoc Health's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TDOC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Teladoc Health analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Teladoc Health: A Closer Look</h2>
Teladoc Health Inc is engaged in virtual care, forging a new healthcare experience with Better convenience, outcomes, and value. Its mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems.
<h3>Teladoc Health: A Financial Overview</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Challenges: Teladoc Health's revenue growth over 3M faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -3.03%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Teladoc Health's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -7.56% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Teladoc Health's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -3.23% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Teladoc Health's ROA excels beyond industry benchmarks, reaching -1.37%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.06.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 8 Analyst Projections For Teladoc Health

Needham analyst Ryan MacDonald reiterates Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) from Hold to Hold.

Reiteration

Needham Reiterates Hold on Teladoc Healthto Hold

Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.34) by 44.12 percent. This is a 61.22 percent increase over losses of $(0.49) per share from the same period last year. The company reported quarterly sales of $629.40 million which beat the analyst consensus estimate of $619.29 million by 1.63 percent. This is a 2.59 percent decrease over sales of $646.13 million the same period last year.

Earnings Beats

CORRECTION: Teladoc Health Q1 Adj. EPS $(0.19) Beats $(0.34) Estimate, Sales $629.40M Beat $619.29M Estimate

Teladoc Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) reported financial results for the first quarter Wednesday after the bell. Here&#8217;s a rundown<a href="https://www.benzinga.com/pressreleases/25/04/g45116556/teladoc-health-reports-first-quarter-2025-results"> of the report</a>.
Q1 Earnings: Teladoc reported first-quarter revenue of $629.4 million, beating the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus estimate</a>&nbsp;of $619.29 million, according to <a href="https://benzinga.grsm.io/gxjhpowx7zks" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>. The company reported a first-quarter loss of 53 cents per share, missing analyst estimates for a loss of 34 cents per share.
Total revenue was down 3% on a year-over-year basis. Revenue fell 4% year-over-year in the U.S., but International revenue grew 6% year-over-year. Here&#8217;s a breakdown of revenue by segment:
<ul>
<li>Integrated Care revenue: up 3% to $389.5 million</li>
</ul>
<ul>
<li>BetterHelp&nbsp;revenue: down 11% to $239.9 million</li>
</ul>
<ul>
<li>Access Fees revenue: down 6% to $525.7 million</li>
</ul>
<ul>
<li>Other revenue: up 16% to $103.6 million</li>
</ul>
Cash flow from operations totaled $15.9 million in the quarter. The company said capital expenditures and capitalized software development costs came in at&nbsp;$31.6 million. Teladoc ended the period with approximately $1.19 billion in cash and cash equivalents.
&#8220;We are pleased with the solid start to 2025. Consolidated revenue and adjusted EBITDA were towards the higher end of our&nbsp;first quarter&nbsp;guidance&nbsp;ranges, including our Integrated Care segment being above our ranges for both measures and BetterHelp segment results in the upper half of our ranges as well,&#8221; said&nbsp;Chuck Divita, CEO of Teladoc Health.
&#8220;We also continue to make progress towards strategic priorities aimed at driving sustainable performance, including advancing our position in virtual mental health.&#8221;
In connection with the earnings release, Teladoc also announced that it acquired virtual mental health therapy provider UpLift for $30 million in an <a href="https://www.benzinga.com/pressreleases/25/04/g45116095/teladoc-health-acquires-uplift-expanding-consumer-access-to-mental-health-care-services-through-co">all-cash transaction</a>. The deal also includes up to $15 million in additional contingent earnout consideration.
Guidance:&nbsp;Teladoc expects second-quarter revenue of $614 million to $633 million, and full-year revenue of $2.47 billion to $2.58 billion. Analysts are anticipating full-year revenue of $2.52 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
The company also lowered its full-year earnings outlook. Teladoc anticipates a 2025 loss of 90 cents to $1.40 per share, down from prior guidance for a loss of 50 cents to $1.10 per share. Analysts are forecasting a loss of 93 cents per share. 
Teladoc executives are currently discussing the quarter on a call with investors and analysts that got started at 4:30 p.m. ET
TDOC Price Action: <a href="https://www.benzinga.com/quote/TDOC" target="_blank" rel="noreferrer noopener">Teladoc shares</a> were down 5.42% in after-hours, trading at $6.80 at the time of publication on Wednesday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/45115442/sell-in-may-and-go-away-looks-outdated-as-mayjuly-data-signal-bullish-sp-500-seasonality">&#8216;Sell In May And Go Away&#8217; Looks Outdated As May–July Data Signal Bullish S&amp;P 500 Seasonality</a></li>
</ul>
Photo: courtesy of Teladoc Health.

Teladoc Health Stock Slides On Q1 Earnings As Company Cuts FY25 Guidance

Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) lowers FY2025 GAAP EPS guidance from $(1.10)-$(0.50) to $(1.40)-$(0.90) vs $(0.93) analyst estimate. Affirms FY2025 sales outlook from $2.47 billion-$2.58 billion to $2.47 billion-$2.58 billion vs $2.52 billion estimate.

Teladoc Health Lowers FY2025 GAAP EPS Guidance from $(1.10)-$(0.50) to $(1.40)-$(0.90) vs $(0.93) Est; Affirms FY2025 Sales Guidance of $2.47B-$2.58B vs $2.52B Est

Teladoc Health acquired UpLift in an all-cash transaction for $30 million, with up to $15 million in additional contingent earnout consideration. UpLift's 2024 revenue was approximately $15 million. The transaction closed on April 30, 2025, and the results of UpLift will be included in the company's BetterHelp reporting segment going forward.
 &nbsp;

Teladoc Health Acquires UpLift In All-cash Transaction For $30M

AEIS

ALGN

ALKT

AMCR

ANSS

ARAY

ATNI

AWRE

BLCO

BLFY

BLKB

BXMT

CACC

CAKE

CDNA

CFLT

CGNX

CHEF

CHRW

CLMB

CMPR

CNMD

CNXN

COCO

COKE

CPSH

CSLR

CSTM

CTOS

CTSH

CVEO

CWAN

CWEN

DFIN

EBAY

ENVX

EQIX

EQNR

ETSY

EXTR

FCPT

FFWM

FINW

FMBH

FORM

FTAI

GEHC

GKOS

GNRC

GRBK

GRMN

GTES

Earnings Scheduled For April 30, 2025

Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-04-30. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Teladoc Health will report an earnings per share (EPS) of $-0.37.
Teladoc Health bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS beat by $0.01, leading to a 13.56% drop in the share price on the subsequent day.
Here's a look at Teladoc Health's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.29</td>
<td>-0.27</td>
<td>-0.34</td>
<td>-0.46</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.28</td>
<td>-0.19</td>
<td>-0.28</td>
<td>-0.49</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-14.000000000000002%</td>
<td>2.0%</td>
<td>-9.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745949754_0.png" alt="eps graph" />
<h3>Teladoc Health Share Price Analysis</h3>
Shares of Teladoc Health were trading at $7.16 as of April 28. Over the last 52-week period, shares are down 42.78%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<h3>Insights Shared by Analysts on Teladoc Health</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Teladoc Health.
The consensus rating for Teladoc Health is Neutral, based on 8 analyst ratings. With an average one-year price target of $11.34, there's a potential 58.38% upside.
<h3>Analyzing Analyst Ratings Among Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Phreesia, Evolent Health and HealthStream, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Phreesia, with an average 1-year price target of $31.8, suggesting a potential 344.13% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Evolent Health, with an average 1-year price target of $13.75, suggesting a potential 92.04% upside.</li>
<li>Analysts currently favor an Neutral trajectory for HealthStream, with an average 1-year price target of $30.0, suggesting a potential 318.99% upside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
Within the peer analysis summary, vital metrics for Phreesia, Evolent Health and HealthStream are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Teladoc Health</td>
<td>Neutral</td>
<td>-3.03%</td>
<td>$451.56M</td>
<td>-3.23%</td>
</tr>
<tr>
<td>Phreesia</td>
<td>Buy</td>
<td>15.45%</td>
<td>$76.11M</td>
<td>-2.46%</td>
</tr>
<tr>
<td>Evolent Health</td>
<td>Outperform</td>
<td>16.27%</td>
<td>$75.71M</td>
<td>-3.00%</td>
</tr>
<tr>
<td>HealthStream</td>
<td>Neutral</td>
<td>5.18%</td>
<td>$49.12M</td>
<td>1.37%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Teladoc Health ranks at the bottom for Revenue Growth and Gross Profit, with negative percentages. It also has the lowest Return on Equity among its peers. The company with the highest Revenue Growth and Gross Profit has a Buy rating. The company with the highest Return on Equity has an Outperform rating.
<h3>Delving into Teladoc Health's Background</h3>
Teladoc Health Inc is engaged in virtual care, forging a new healthcare experience with Better convenience, outcomes, and value. Its mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems.
<h3>Teladoc Health's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Negative Revenue Trend: Examining Teladoc Health's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -3.03% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Teladoc Health's net margin is impressive, surpassing industry averages. With a net margin of -7.56%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Teladoc Health's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -3.23%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Teladoc Health's ROA excels beyond industry benchmarks, reaching -1.37%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.06.
<a href="https://www.benzinga.com/quote/TDOC/earnings">To track all earnings releases for Teladoc Health visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Teladoc Health

Citigroup analyst Daniel Grosslight maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Neutral and lowers the price target from $11 to $8.75.

Citigroup Maintains Neutral on Teladoc Health, Lowers Price Target to $8.75

Jefferies analyst Glen Santangelo maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Hold and lowers the price target from $10 to $8.

Jefferies Maintains Hold on Teladoc Health, Lowers Price Target to $8

In the preceding three months, 8 analysts have released ratings for Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>), presenting a wide array of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $12.25, a high estimate of $16.00, and a low estimate of $8.00. This current average represents a 1.53% decrease from the previous average price target of $12.44. 
<img src="https://www.benzinga.com/files/images/story/2025/1744372878_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Teladoc Health is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Allen Lutz &#x7C;B of A Securities &#x7C;Lowers &#x7C;Neutral &#x7C; $8.00&#x7C;$9.50 &#x7C; 
&#x7C;David Roman &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Buy &#x7C; $13.00&#x7C;$16.00 &#x7C; 
&#x7C;Jessica Tassan &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $12.00&#x7C;$13.00 &#x7C; 
&#x7C;David Roman &#x7C;Goldman Sachs &#x7C;Raises &#x7C;Buy &#x7C; $16.00&#x7C;$14.00 &#x7C; 
&#x7C;Allen Lutz &#x7C;B of A Securities &#x7C;Raises &#x7C;Neutral &#x7C; $13.50&#x7C;$11.50 &#x7C; 
&#x7C;Allen Lutz &#x7C;B of A Securities &#x7C;Raises &#x7C;Neutral &#x7C; $11.50&#x7C;$10.50 &#x7C; 
&#x7C;Sean Dodge &#x7C;RBC Capital &#x7C;Raises &#x7C;Outperform &#x7C; $12.00&#x7C;$11.00 &#x7C; 
&#x7C;Michael Wiederhorn &#x7C;Oppenheimer &#x7C;Lowers &#x7C;Outperform &#x7C; $12.00&#x7C;$14.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Teladoc Health. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Teladoc Health compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Teladoc Health's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Teladoc Health's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/TDOC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Teladoc Health analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Teladoc Health</h2>
Teladoc Health Inc is engaged in virtual care, forging a new healthcare experience with Better convenience, outcomes, and value. Its mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems.
<h3>A Deep Dive into Teladoc Health's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Decline in Revenue: Over the 3M period, Teladoc Health faced challenges, resulting in a decline of approximately -3.03% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Teladoc Health's net margin excels beyond industry benchmarks, reaching -7.56%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Teladoc Health's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -3.23%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Teladoc Health's ROA excels beyond industry benchmarks, reaching -1.37%. This signifies efficient management of assets and strong financial health.
Debt Management: Teladoc Health's debt-to-equity ratio is below the industry average at 1.06, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

B of A Securities analyst Allen Lutz maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Neutral and lowers the price target from $9.5 to $8.

B of A Securities Maintains Neutral on Teladoc Health, Lowers Price Target to $8

New features for members and customers include:
<ul>
<li>A premium subscription to <a href="https://www.bettersleep.com">BetterSleep</a>, the award-winning app that promotes sleep quality and well-being.</li>
<li>Access to a registered dietitian for 1:1 support, medical nutrition therapy and personalized nutrition planning.</li>
<li>Proactive outreach from expert health coaches for those at highest risk.</li>
<li>Convenient at-home testing for key cardiometabolic measures, including A1c and blood lipids.</li>
<li>Dynamic health insights that leverage patient-reported data and inputs from Teladoc Health's connected devices— blood glucose meters, blood pressure monitors and connected scales—as well as CGM devices to help empower better outcomes.</li>
<li>Seamless integration with Teladoc Health's 24/7 Care and primary care providers, as well as <a href="https://www.teladochealth.com/organizations/connected-care-partners">connected care partners</a> who can care for related conditions like joint pain and digestive health needs.</li>
</ul>

General

Teladoc Health Introduced Its Next Generation Cardiometabolic Health Program To Improve Population Health And Prevent The Progression Of Diabetes, Hypertension And Obesity

Shares of Teladoc Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) have been under pressure since the fourth-quarter earnings release on Feb. 26.
JPMorgan analysts blamed the persistent underperformance of BetterHelp and "a more challenging operating backdrop complicated by renewed macroeconomic concerns.&#8221;
The Teladoc Health Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/586e4055351b9b00018beea6/lisa-gill">Analyst Lisa Gill</a> reaffirmed a Neutral rating, while reducing the price target from $13 to $11.
The Teladoc Health Thesis: The company is likely to generate Q1 revenues of $617.5 million, versus consensus of $619 million.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
The adjusted EBITDA is likely to be $52.8 million, versus consensus of $53 million, she added.
The analyst projected full-year revenue estimate at $2.52 billion. That&#8217;s slightly higher than the consensus of $2,519 million.
The analyst also has a 2026 estimate of $2.56 billion, versus consensus of $2.558 billion.
Gill lowered the <a>adjusted EBITDA estimates for 2025 and 2026 from $311 million to $294 million and from $333 million to $314 million</a>, respectively.
"Our revenue estimates assume Integrated Care growth of +2% and +3% and we model BetterHelp down -7.7% and flat in FY25 and FY26, respectively," she wrote.
While the scale of Teladoc Health platform and the longer-term strategic direction are good, "there is more work to be done," Gill added.
Price Action: Shares of Teladoc Health had risen by 0.06% to $8.62 at the time of publication on Monday.
Read More: 
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/02/43949618/cisco-and-nvidia-expand-ai-partnership-secure-us-government-authorization-for-cloud-security">Teladoc Health Partners With Eli Liily&#8217;s LillyDirect to Expand Access to Zepbound For Weight Loss</a></li>
</ul>
Photo courtesy of Teladoc
&nbsp;&nbsp;

Analyst Color

Teladoc Health Q1 Preview: Analyst Says Strategic Direction Is Good, But There's 'More Work To Be Done'

The rise of cash-pay GLP-1 prescriptions, fueled by programs like LillyDirect, is generating plenty of buzz—but JPMorgan analyst Lisa C. Gill isn't convinced this is a major shake-up for the <a href="https://www.benzinga.com/general/health-care">healthcare supply chain</a>. 
According to Gill, while Eli Lilly And Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) direct-to-consumer push is putting pressure on compounding pharmacies, it's not a volume shift that should worry pharmaceutical distributors.
LillyDirect's fulfillment model bypasses traditional distributors by shipping straight from Lilly's warehouses via partners like Amazon.com Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) Amazon Pharmacy and Truepill.
Read Also: <a href="https://www.benzinga.com/25/03/44175948/alzheimers-drugs-from-eli-lilly-and-biogen-still-deemed-too-costly-for-nhs-funding">Alzheimer&#8217;s Drugs From Eli Lilly And Biogen Still Deemed Too Costly For NHS Funding</a>
That means these sales aren't "lost" volume for distributors—they were never in their lane to begin with. Plus, GLP-1 distribution has never been a major profit driver for pharma distributors, so even if some volume moves from compounding pharmacies to LillyDirect, Gill sees minimal impact on their bottom lines.
<h2 class="wp-block-heading">The Numbers Tell The Story</h2>
LillyDirect's GLP-1 play is still a sliver of the market. Even assuming 5% of 2025's estimated 16.2 million Zepbound prescriptions run through LillyDirect, that's just 800,000 scripts &#8211; a drop in the 4.65 billion-prescription U.S. market bucket. 
Translation? This isn't a disruption; it's a strategic skirmish.
<h2 class="wp-block-heading">A Win For Teladoc?</h2>
One clear winner in this shake-up could be Teladoc Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>). The company is <a href="https://www.benzinga.com/general/health-care/25/03/44170605/teladoc-health-partners-with-eli-liilys-lillydirect-to-expand-access-to-zepbound-for-weight-loss">integrating LillyDirect into its Chronic Care Weight Management program</a>, potentially boosting enrollments. With GLP-1 costs squeezing insurers, this partnership could make Teladoc's weight management offering more attractive to employers looking for coverage alternatives.
LillyDirect may be making waves, but for pharma distributors, it's business as usual. 
As Gill puts it, the GLP-1 cash-pay trend is more about pressuring compounding pharmacies than upending the broader supply chain. 
Investors eyeing big disruptions might want to look elsewhere.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/global/25/03/44182967/weight-loss-drugs-soar-while-global-obesity-rates-climb-to-hit-50-of-adults-by-2050-says-new-report">Weight Loss Drugs Soar While Global Obesity Rates Climb, To Hit 50% Of Adults By 2050 Says New Report</a></li>
</ul>
Image: Shutterstock

Biotech

Long Ideas

AMZN

Eli Lilly Direct-To-Consumer Push Shouldn't Worry Distributors: JPMorgan

Press Releases

Cylinder joins Teladoc Health's Connected Care Program to expand access to virtual digestive care

Carrum Health Selected by Teladoc Health as Centers of Excellence Partner

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teladoc Health, Inc. - TDOC

AI Influence on Medical Diagnostics Generating Billion Dollar Revenues While Growing Adoption Reduces Healthcare Costs

Teladoc Health Introduces Next Generation Cardiometabolic Health Program

Teladoc Health to Announce First Quarter 2025 Financial Results

Teladoc Health Acquires UpLift, Expanding Consumer Access to Mental Health Care Services Through Covered Benefits

Teladoc Health Reports First Quarter 2025 Results

Teladoc Health Announces Employee Inducement Awards under NYSE Rule 303A.08

Small Cap

Opinion

Tech That Listens, Learns, and Diagnoses: AI's Breakout Moment in Healthcare

AVAI

BFRG

CLOV

HWAIF

TALK

TSX:AIDX

Firefly Neuroscience, Inc. - Common Stock

Firefly Neuroscience

American Well Corporation Class A Common Stock

American Well

CareCloud

Certara

Claritev Corporation Class A Common Stock

Claritev

Definitive Healthcare Corp. - Class A Common Stock

Definitive Healthcare

Doximity

DarioHealth

Evolent Health

Forian

GoodRx Holdings, Inc. - Class A Common Stock

GoodRx Holdings

Health Catalyst

HealthStream

icad

LifeMD

OptimizeRx

Phreesia

Pheton Holdings Ltd - Class A Ordinary Shares

Pheton Holdings

Schrodinger

Simulations Plus

Sophia Genetics

TruBridge

Veeva Systems

VSee Health

Waystar Holding

Wells Fargo

Canaccord Genuity

Goldman Sachs

Stifel

Evercore ISI Group

이 10개 중형주는 지난주 최고의 성과를 거두었습니다. 그것들이 당신의 포트폴리오에 있나요?
1. 킹소프트 클라우드(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>)의 주식은 34.77% 상승했다.
2. 오클로(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>)의 주식은 33.36% 급등했다. 이사회 멤버인 크리스 라이트(Chris Wright)가 2025년 2월 3일 미국 에너지 장관으로 임명되면서 <a href="https://www.benzinga.com//node/43525625" target="_blank" rel="noreferrer noopener">오클로 이사회에서 사임</a>했다.
3. AST 스페이스모바일(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>)의 주식은 캔터 피츠제럴드의 애널리스트 콜린 캔필드(Colin Canfield)가 &#8220;비중확대&#8221; 등급과 <a href="https://www.benzinga.com/quote/ASTS/analyst-ratings" target="_blank" rel="noreferrer noopener">$30의 목표 주가</a>를 제시한 후 30.98% 상승했다.
4. 브이넷 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNET#NASDAQ">VNET</a>)의 주식은 29.12% 급등했다.
5. 텔레닥 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>)의 주식은 회사가 캐터펄트 헬스(Catapult Health)를 <a href="https://www.benzinga.com//node/43490439" target="_blank" rel="noreferrer noopener">현금</a> 6,500만 달러에 인수할 것이라고 발표한 후 27.46% 상승했다.
6. GDS 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>)의 주식은 25.68% 상승했다. 최근 중국이 일부 미국 수입품에 대한 관세를 인상했으며, 미국이 쉬인과 테무를 &#8216;강제 노동&#8217; 목록에 추가하는 방안을 검토하고 있다는 보도가 나왔다.
7. 매그나이트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNI#NASDAQ">MGNI</a>)의 주식은 23.08% 상승했다. <a href="https://www.businessinsider.com/elon-musk-x-signs-programmatic-ad-partnership-magnite-2025-2" target="_blank" rel="noreferrer noopener">일론 머스크의 X(구 트위터)</a>와 파트너십을 체결했다는 보도가 나온 후이다.
8. 솔라윈즈 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWI#NYSE">SWI</a>)의 주식은 23.05% 상승했습니다. 회사가 턴/리버 캐피털(Turn/River Capital)이 <a href="https://www.benzinga.com//node/43559292" target="_blank" rel="noreferrer noopener">44억 달러에 인수할 것이라고 발표</a>했다.
9. 라이언스게이트 엔터테인먼트 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LGF#NYSE">LGF</a>)의 주식은 22.68% 상승했다. 회사가 3분기 실적이 예상보다 좋게 나타났다고 보고했다.
10. 아이렌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>)의 주식은 22.02% 상승했다. <a href="https://www.benzinga.com//node/43524343" target="_blank" rel="noreferrer noopener">1월에 525 비트코인</a>(CRYPTO: BTC/USD)를 채굴했다고 보고한 후이다.
다음 읽기:
<ul>
<li></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ED%8C%94%EB%9E%80%ED%8B%B0%EC%96%B4-%EC%8A%88%ED%8D%BC-%EB%A7%88%EC%9D%B4%ED%81%AC%EB%A1%9C-%EC%BB%B4%ED%93%A8%ED%84%B0-%EB%B0%8F-%EC%8A%A4%ED%8F%AC%ED%8B%B0%ED%8C%8C%EC%9D%B4-%EB%93%B1-%EC%A7%80/" target="_blank" rel="noopener">팔란티어, 슈퍼 마이크로 컴퓨터 및 스포티파이 등 지난주 상승한 10개 대형주 (2월 3일-2월 7일)</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%97%90%EC%8A%A4%ED%8B%B0-%EB%A1%9C%EB%8D%94-%EB%AA%A8%EB%8D%94%EB%82%98-%EB%B0%8F-%ED%8E%98%EC%9D%B4%ED%8C%94-%EB%93%B1-%EC%A7%80%EB%82%9C%EC%A3%BC-%ED%95%98%EB%9D%BD%ED%95%9C-10%EA%B0%9C%EC%9D%98/" target="_blank" rel="noopener">에스티 로더, 모더나 및 페이팔 등 지난주 하락한 10개의 대형주 (2월 3일-7일)</a></li>
</ul>
사진출처: ASTS
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

텔레닥 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>)의 주가는 회사가 <a href="https://www.benzinga.com/pressreleases/24/10/g41635843/teladoc-health-reports-third-quarter-2024-results" target="_blank" rel="noopener" data-google-interstitial="false">분석가 기대치를 뛰어넘는</a> 3분기 재무 결과를 보고한 후 수요일 시간외 거래에서 11% 이상 급등했다.
<ul>
<li>3분기 매출: 6억 4,051만 달러, <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noopener" data-google-interstitial="false">예상치</a>인 6억 3,116만 달러를 상회</li>
</ul>
<ul>
<li>3분기 EPS: 19센트 손실, 예상 손실 27센트보다 개선됨</li>
</ul>
총 매출은 전년 대비 3% 감소했다. 통합 케어 부문 매출은 전년 대비 2% 증가했으며, 베터헬프(BetterHelp) 부문 매출은 10% 감소했다. 미국 매출은 전년 대비 6% 감소했지만, 국제 매출은 15% 증가했다.
3분기 영업 현금 흐름은 1억 1,020만 달러였으며, 이 회사는 분기 동안 7,900만 달러의 잉여 현금 흐름을 생성했다고 밝혔다.
&#8220;2024년을 마무리하면서 우리는 긴급하게 움직이고 있으며, 우리가 제공하는 복잡하고 역동적인 시장에서의 리더십 위치를 보다 효과적으로 활용하기 위해 변화를 만들고 있다. 우리는 앞으로 더 많은 작업이 있으며, 2025년은 중요한 재편성의 해가 될 것이다. 우리의 초점은 일관된 성과를 제공하고 장기적인 주주 가치를 증대시키는 것이다&#8221;라고 텔레닥 헬스의 CEO인 척 디비타(Chuck Divita)가 말했다.
가이던스: 텔레닥은 4분기 통합 케어 부문 매출이 전분기 대비 0%에서 2.5% 증가할 것으로 예상하고 있다. 연간 통합 케어 부문 매출은 저단위에서 중단위 성장할 것으로 예상하고 있다.
TDOC 주가 움직임: 텔레닥의 주식은 수요일 애프터 마켓에서 11.63% 상승하여 9.89달러에 거래되었다.
다음 읽어보기: 
• <a href="https://kr.benzinga.com/news/usa/stocks/%EB%A9%94%ED%83%80-3%EB%B6%84%EA%B8%B0-%EC%8B%A4%EC%A0%81-%EB%A7%A4%EC%B6%9C-%EB%B0%8F-eps-%EC%98%88%EC%83%81-%EC%83%81%ED%9A%8C-%EC%9D%BC%EC%9D%BC-%ED%99%9C%EC%84%B1-%EC%82%AC%EC%9A%A9%EC%9E%90-5/" target="_blank" rel="noopener">메타 플랫폼스 3분기 실적: 매출 및 EPS 예상치 상회, 일일 활성 사용자 5% 증가, AI 분야 강력한 모멘텀</a>
사진: Teladoc 제공.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

수요일에 캐시 우드가 주도하는 아크 인베스트(Ark Invest)는 어드밴스드 마이크로 디바이시스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), 핀터레스트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>), 코인베이스 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>)에서 상당한 거래를 했다. 아크는 파괴적인 혁신에 중점을 두는 것으로 유명하다.
AMD 거래
아크 인베스트는 ARK Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)와 ARK Next Generation Internet ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>)를 통해 AMD 주식 328,527주를 매입했다. 거래 금액은 4,746만 달러에 이른다. AMD 주가는 수요일 정규 세션을 4.4% 상승한 144.48달러에 마감했다.
이러한 움직임은 AMD의 2분기 실적 보고서가 예상을 뛰어넘고 회사 주가의 반등으로 이어진 이후에 나온 것이다. AMD의 분기별 수치는 주로 데이터 센터 매출의 강세와 클라이언트 비즈니스의 긍정적인 성과에 힘입어 <a href="https://www.benzinga.com/news/earnings/24/07/40051646/amd-shares-rebound-after-chipmaker-posts-q2-beat-guidance-tops-expectations-ceo-lisa-su-says-ai-bus" target="_blank" rel="noopener" data-google-interstitial="false">전년 대비 매출과 이익이 증가</a>한 것으로 나타났다.
AMD의 주가는 실적 보고서 이후 크게 급등하여 유명 투자자들이 이 칩 제조업체에 재투자하기로 한 <a href="https://www.benzinga.com/markets/equities/24/07/40057114/amds-results-proved-our-plan-to-reinvest-in-the-stock-was-right-says-jim-cramer-who-credits-lisa" target="_blank" rel="noopener" data-google-interstitial="false">결정을 입증</a>했다. 이번 성과에는 이 회사의 새로운 인공지능 칩인 MI300X가 중추적인 역할을 했다.
핀터레스트(PINS) 거래
아크 인베스트는 또한 Ark Fintech Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>), ARKK 및 ARKW ETF 전반에 걸쳐 핀터레스트 지분을 늘렸다. 총 매입 주식수는 398,257주이다. 핀터레스트 주식 구매 금액은 종가 31.95달러를 기준으로 약 1,272만 달러이다.
이 결정은 핀터레스트의 2분기 실적 보고서에 따른 것으로, 매출과 EPS 추정치를 웃돌았다. 그러나 핀터레스트의 3분기 <a href="https://www.benzinga.com/news/earnings/24/07/40051745/pinterest-q2-earnings-revenue-eps-beat-but-weak-guidance-weighs-on-shares" target="_blank" rel="noopener" data-google-interstitial="false">약한 지침</a>은 주가에 부담을 주었다. 그럼에도 불구하고 아크 인베스트의 움직임은 이 회사의 장기적인 전망에 대한 자신감을 시사한다.
특히 핀터레스트의 경쟁사인 마크 저커버그가 이끄는 메타 플랫폼스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)가 <a href="https://www.benzinga.com/news/earnings/24/07/40081701/meta-platforms-q2-earnings-revenue-beat-eps-beat-strong-guidance-meta-ai-is-on-track-to-be-the-most">강력한 2분기 실적</a>을 발표한 날 거래가 이루어졌다.
코인베이스(COIN) 거래
아크 인베스트는 ARKW ETF에서 코인베이스의 주식 12,077주를 매각했다. COIN 매도의 총 가치는 종가 224.36달러를 기준으로 약 270만 달러이다.
이번 매각은 비트코인과 이더리움 ETF 승인이 상위 2개 암호화폐인 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)과 이더리움(CRYPTO:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/eth-usd" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for ETH/USD">ETH</a>)에 대한 수요에 미치는 영향을 보여줄 것으로 예상되는 코인베이스의 2분기 실적 보고서에 앞서 이루어졌다.
이란 최고 지도자가 이스라엘에 대한 직접 공격을 명령한 후 비트코인은 66,500달러에서 64,000달러 초반 수준으로 하락하여 <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/40088529/bitcoin-ethereum-dogecoin-slip-amid-flare-up-of-iran-israel-tensions-analyst-says-a-big-mo" target="_blank" rel="noopener" data-google-interstitial="false">시장 정서에 극적인 변화</a>와 광범위한 청산을 일으켰다.
기타 주요 거래:
아크 인베스트는 ARKK ETF를 통해 줌 비디오 커뮤니케이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) 및 텔레닥 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/tdoc#NYSE">TDOC</a>)의 주식을 매도했다.
아크 인베스트는 ARKG ETF를 통해 가든트 헬스(GH)와 인텔리아 테라퓨틱스(NTLA)의 주식을 매입했다. 아크 인베스트는 ARKW ETF에서 베라사이트(VCYT)의 주식을 매도했다.
다음 읽어보기: 
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ec%9d%b4%eb%9e%80%ec%9d%98-%ec%9d%b4%ec%8a%a4%eb%9d%bc%ec%97%98%ec%97%90-%eb%8c%80%ed%95%9c-%eb%b3%b4%eb%b3%b5-%eb%a7%b9%ec%84%b8%eb%a1%9c-%ec%9c%a0%ea%b0%80-2023%eb%85%84-10%ec%9b%94-%ec%9d%b4/" target="_blank" rel="noopener">이란의 이스라엘에 대한 보복 맹세로 유가 2023년 10월 이후 최대 일일 급등: UN, 긴급 회의 개최</a></li>
</ul>
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 통해 작성되었으며 <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>에 의해 편집되었습니다.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

원격 의료 회사인 텔레닥 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/tdoc#NYSE">TDOC</a>)는 <a href="https://www.benzinga.com/earnings" target="_blank" rel="noopener" data-google-interstitial="false">수요일 시장 마감</a> 후 2분기 재무 결과를 발표했다.
주요 하이라이트는 다음과 같다.
어떤 일이 (What Happened): 텔레닥은 2분기 매출이 6억 4,240만 달러로 전년 대비 2% 감소했다고 보고했다. <a href="https://pro.benzinga.com/feature/newsfeed/?gspk=bHVrZWphY29iaTUzNDg&amp;gsxid=tdEE0VrK8Jeg&amp;ref=lukejacobi5348" target="_blank" rel="noopener">Benzinga Pro</a>의 데이터에 따르면 총 매출은 월가 합의 추정치인 6억 4,970만 달러를 밑돌았다.
이 회사는 2분기에 주당 28센트의 손실을 보고했는데, 이는 월가의 추정 주당 35센트 손실을 뛰어넘는 수치이다.
통합 케어 부문 매출은 3억 7,740만 달러로 해당 분기에 전년 대비 5% 증가했으며, 베터헬스(BetterHealth) 부문 매출은 2억 6,500만 달러로 분기에 전년 대비 9% 감소했다.
2분기 미국 매출은 5억 4,080만 달러로 전년 동기 대비 4% 감소했다. 2분기 해외 매출은 1억 160만 달러로 전년 동기 대비 12% 증가했다.
&#8220;텔레닥 헬스에 입사하게 되어 앞으로 회사를 이끌 기회를 얻게 되어 우리의 강점을 기반으로 더 높은 수준의 성과를 창출할 수 있게 되어 기쁘다. 우리의 확장된 위치, 핵심 역량, 재능 있는 직원들은 이러한 측면에서 우리를 잘 배치한다&#8221;고 텔레닥 핼스의 CEO인 척 디비타(Chuck Divita)가 말했다.
다음은: 이 회사는 통합 운영과 베터헬스 부문에 대한 연간 재무 전망을 철회한다고 밝혔다. 이 회사는 통합 운영에 대한 3년 전망도 철회했다.
디비타는 &#8220;통합 진료 부문에서 탄탄한 성과를 달성한 반면 베터헬스 부문에서 계속되는 역풍이 전반적인 결과에 영향을 미쳤다&#8221;고 말했다. &#8220;우리는 시간이 지남에 따라 회사 전체에서 더 큰 가치를 창출하기 위해 긴급하게 우리 앞에 놓인 작업을 해결하는 데 집중하고 있다.&#8221;
TDOC 주가 움직임: 수요일 애프터마켓에서 텔라닥의 주식은 14.35% 하락한 8.06달러에 거래되었다. 이는 52주 최저가인 8.73달러를 하회하는 수치이다.
사진: Ground Picture/Shutterstock.com
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

텔라닥 헬스:  엇갈린 2분기 실적과 연간 전망 지침 철회로 주가는급락, 52주 최저치 돌파

수요일에 캐시 우드가 이끄는 아크 인베스트(Ark Invest)는 이 회사의 인상적인 2분기 납품 실적에 힘입은 최근 상승세에도 불구하고 테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)의 상당 수의 주식을 매각하여 주목할만한 움직임을 보였다.
테슬라 주식
아크 인베스트는 ARK Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)를 통해 테슬라 지분을 줄여 13,213주를 매각했다. 이번 거래는 테슬라의 주가가 최근 화요일에 10.20% 급등해 4월 말 이후 최고의 장중 거래를 기록했다는 점을 감안하면 놀라운 일이었다. 특히 화요일에 아크 인베스트는 <a href="https://www.benzinga.com/markets/equities/24/07/39611275/cathie-woods-ark-invest-sells-tesla-shares-worth-14-5m-amid-rally-driven-by-q2-delivery-numbers-">1,450만 달러</a> 상당의 테슬라 주식을 매각했다.
이러한 상승은 주로 일론 머스크가 이끄는 이 회사의 <a href="https://www.benzinga.com/markets/equities/24/07/39595720/tesla-deliveries-fall-for-second-straight-quarter-but-stock-takes-off-as-q2-numbers-exceed-expec">2분기 실적</a>에 의해 주도되었다. 테슬라는 예상 차량 439,000대를 크게 초과하는 443,956대를 인도했다고 보고했다. 이러한 놀라운 상승세는 랠리를 촉진하여 주가를 2024년 최고치로 끌어올렸다. 판매의 대부분은 저렴한 모델 3 및 Y에서 이루어졌으며, 더 비싼 모델 X, S 및 신형 사이버트럭에서는 21,551대만 판매되었다.
최종 종가 246.39달러를 기준으로 수요일에 판매된 주식의 가치는 약 325만 달러에 달한다. 이날 테슬라 주가는 6.5% 급등했다.
기타 중요한 거래:
<ul>
<li>아크 인베스트의 ARKF 펀드는 텔레닥(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>)의 주식을 팔았다.</li>
<li>ARKG 펀드는 인텔리아 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>)의 주식을 2,551주 매수하고, 버브 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>)의 주를 팔았다.</li>
<li>ARKK 펀드는 아처 에비에이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NASDAQ">ACHR</a>)의 주를 사고, 깅코 바이오웍스 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNA#NYSE">DNA</a>)의 주를 팔았다.</li>
<li>ARKQ 펀드는 에어로바이런먼트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>)의 주를 팔았다. ARKX 펀드는 블레이드 에어 모빌리티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDE#NASDAQ">BLDE</a>)의 주를 샀다.</li>
</ul>
이미지는 셧터스톡을 통해 제공됨
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 사용하여 <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>이 편집했다

ETFs

아크 인베스트가 예상을 넘는 2분기 배송 실적에도 $3.25백만 규모 테슬라 주식 매도 추가

Comments

Teladoc Health

뉴스

에 대한 최신 뉴스 Teladoc Health (NYSE:TDOC) 주식

일요일, 2월 09, 2025

목요일, 10월 31, 2024

목요일, 8월 01, 2024

수요일, 7월 31, 2024

목요일, 7월 04, 2024

화요일, 7월 02, 2024

목요일, 6월 27, 2024

화요일, 6월 25, 2024

목요일, 6월 13, 2024

화요일, 6월 11, 2024

화요일, 4월 16, 2024

금요일, 4월 12, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌